Keeping an eye on monitoring
Philippe Dro is taking over the helm of NeMoDevices AG, a Switzerland-based developer in the innovative monitoring of brain blood flow and oxygen levels. The previous CEO Michael Oberle will serve as COO in future.
Philippe Dro previously served as CEO of GlycoVaxyn AG, a Swiss biotech startup in vaccines, which was acquired by GSK in early 2015. Before GlycoVaxyn, Dro was CEO of EndoArt SA, a medical technology company spin-out from the École polytechnique fédérale de Lausanne (EPFL), which was acquired by Allergan in early 2007. Dro holds a PhD in pharmacy from the University of Grenoble as well as an MBA from Ecole Superieure de Commerce de Lyon and Cranfield School of Management in the United Kingdom.
NOD-Proteindesign.Andreas Heddergott/TUM.jpg
Certest
Consilium